Yonsei University
- Country
- đ°đˇSouth Korea
- Ownership
- Private
- Established
- 1885-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.yonsei.ac.kr
A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)
- Conditions
- Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 49
- Registration Number
- NCT03770988
- Locations
- đ°đˇ
Severance Hospital, Seoul, Korea, Republic of
Low- and Moderate-intensity Statin and Clinical Outcome of Primary Prevention in Individuals Aged >75 Years: the SCOPE-75 RCT Study
- Conditions
- Healthy Elderly Individuals With High LDL-cholesterol or Risk of Cardiovascular Disease
- Interventions
- Drug: Low intensity statinDrug: Moderate intensity statin
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 2484
- Registration Number
- NCT03770312
- Locations
- đ°đˇ
Division of Cardiology, Cardiovascular Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease
- Conditions
- Healthy Participants With Moderate and High Cardiovascular Risk
- Interventions
- Other: Withdrawal of aspirin
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 4118
- Registration Number
- NCT03757156
- Locations
- đ°đˇ
Division of Cardiology, Cardiovascular Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity
- Conditions
- Vitiligo
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 43
- Registration Number
- NCT03741738
- Locations
- đ°đˇ
Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of
A Clinical Trial of Silk Peptide for the Evaluation of Efficacy on Immune Function
- Conditions
- Normal Healthy Subjects
- Interventions
- Dietary Supplement: Investigational Product (Silk Peptide)Dietary Supplement: Control Group - Placebo Product
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 110
- Registration Number
- NCT03739970
- Locations
- đ°đˇ
Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University., Seoul, Korea, Republic of
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
- Conditions
- HypopharynxStage II-IVB Operable HNSCC Oral CavityOropharynxLarynx
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 48
- Registration Number
- NCT03737968
- Locations
- đ°đˇ
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
A Study on the Effectiveness and Safety Evaluation of Combination Therapy With 1,927nm Thulium Laser and Fractional Microneedle Radiofrequency Equipment for Improvement of Skin Aging
- Conditions
- Wrinkle
- Interventions
- Device: LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR))Device: LASEMED laser(The Thulium laser with 1,927nm wavelength)
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 26
- Registration Number
- NCT03739398
- Locations
- đ°đˇ
Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of
Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia
- Conditions
- Dyslipidemias
- Interventions
- Behavioral: Life-style modificationDrug: Treatment of pitavastatin 4 mg qd for 12 weeks
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 50
- Registration Number
- NCT03730038
- Locations
- đ°đˇ
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Tailored Therapeutic Model According to the Expression of Genes in Inflammatory Bowel Disease Patients
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Genetic: genotyping for three genes (TPMT, NUDT15 and FTO)Other: non-genotyping
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 215
- Registration Number
- NCT03719118
- Locations
- đ°đˇ
Severance Hospital, Seoul, Korea, Republic of
đ°đˇKorea University Hospital, Seoul, Korea, Republic of
đ°đˇEwha Medical Research Institute, Seoul, Korea, Republic of
Effects of End-effector Type Robot Assisted Gait Therapy on Gait Pattern and Energy Consumption in Chronic Post-stroke Hemiplegic Patients
- Conditions
- Chronic Post-stroke Hemiplegic Patients
- Interventions
- Device: Robot Assisted Gait TherapyDevice: Conventional Gait Therapy
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 40
- Registration Number
- NCT03709329
- Locations
- đ°đˇ
Department of Rehabilitation Medicine, Severance Hospital, Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of